Harnessing insights from live patient tumor cells to develop better therapeutic options for cancer patients

  • Our proprietary CELsignia platform analyzes oncogenic pathways in live tumor cells.
  • This enables us to discover cancer drivers molecular tests cannot identify.
  • We translate our discoveries into the development of new therapeutic options for cancer patients.
Gedatolisib Press Release
Our Pipeline

Offering hope to cancer patients means finding the driver of their cancer.

  • Genomic testing cannot diagnose many patients’ cancer driver, limiting treatment options.
  • CELsignia analyzes a patient’s own live tumor cells to reveal complex oncogenic activity.
  • These insights reveal new cancer drivers so patients can be more precisely matched to the right targeted therapy.
  • Celcuity is now developing, directly and through collaborations, targeted therapies to treat these patients.